Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Intellia Therapeutics (NTLA) Cash from Operations: 2015-2024

Historic Cash from Operations for Intellia Therapeutics (NTLA) over the last 10 years, with Dec 2024 value amounting to -$348.9 million.

  • Intellia Therapeutics' Cash from Operations rose 9.36% to -$76.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$410.6 million, marking a year-over-year decrease of 15.11%. This contributed to the annual value of -$348.9 million for FY2024, which is 11.47% up from last year.
  • According to the latest figures from FY2024, Intellia Therapeutics' Cash from Operations is -$348.9 million, which was up 11.47% from -$394.1 million recorded in FY2023.
  • Over the past 5 years, Intellia Therapeutics' Cash from Operations peaked at -$49.9 million during FY2020, and registered a low of -$394.1 million during FY2023.
  • For the 3-year period, Intellia Therapeutics' Cash from Operations averaged around -$358.8 million, with its median value being -$348.9 million (2024).
  • Per our database at Business Quant, Intellia Therapeutics' Cash from Operations soared by 51.65% in 2020 and then crashed by 350.85% in 2021.
  • Over the past 5 years, Intellia Therapeutics' Cash from Operations (Yearly) stood at -$49.9 million in 2020, then crashed by 350.85% to -$225.0 million in 2021, then tumbled by 48.11% to -$333.3 million in 2022, then dropped by 18.24% to -$394.1 million in 2023, then climbed by 11.47% to -$348.9 million in 2024.